Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival BioSpaceIndirect comparisons between BridgeBio's Attruby and Pfizer's tafamidis products showed a numerical survival benefit with the biotech's drug.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug. Cardiovascular Read full story Post navigation Previous: Novo says high-dose Wegovy can cause 28% weight lossNext: EU agrees plan to tackle essential medicine shortages Related Stories Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026 Clinical Data Viridian data lift prospects for thyroid eye disease drug pharminent May 5, 2026
